Unique Clinicopathologic Features Characterize <i>ALK</i> -Rearranged Lung Adenocarcinoma in the Western Population

Scott J. Rodig(Brigham and Women's Hospital), Mari Mino–Kenudson(Brigham and Women's Hospital), Sanja Đačić(Brigham and Women's Hospital), Beow Y. Yeap(Brigham and Women's Hospital), Alice T. Shaw(Brigham and Women's Hospital), Justine A. Barletta(Brigham and Women's Hospital), Hannah Stubbs(Brigham and Women's Hospital), Kenny Law(Brigham and Women's Hospital), Neal I. Lindeman(Brigham and Women's Hospital), Eugene J. Mark(Brigham and Women's Hospital), Pasi A. Jänne(Brigham and Women's Hospital), Thomas J. Lynch(Brigham and Women's Hospital), Bruce E. Johnson(Brigham and Women's Hospital), A. John Iafrate(Brigham and Women's Hospital), Lucian R. Chirieac(Brigham and Women's Hospital)
Clinical Cancer Research
August 12, 2009
Cited by 682Open Access
Full Text

Abstract

PURPOSE: The anaplastic large cell kinase gene (ALK) is rearranged in approximately 5% of lung adenocarcinomas within the Asian population. We evaluated the incidence and the characteristics of ALK-rearranged lung adenocarcinomas within the western population and the optimal diagnostic modality to detect ALK rearrangements in routine clinical practice. EXPERIMENTAL DESIGN: We tested 358 lung adenocarcinomas from three institutions for ALK rearrangements by fluorescent in situ hybridization (FISH) and immunohistochemistry with and without tyramide amplification. The clinicopathologic characteristics of tumors with and without ALK rearrangements were compared. RESULTS: We identified 20 (5.6%) lung adenocarcinomas with ALK rearrangements within our cohort of western patients. ALK rearrangement was associated with younger age (P = 0.0002), never smoking (P < 0.0001), advanced clinical stage (P = 0.0001), and a solid histology with signet-ring cells (P < 0.0001). ALK rearrangement was identified by FISH in 95% of cases and immunohistochemistry with and without tyramide amplification in 80% and 40% of cases, respectively, but neither FISH nor immunohistochemistry alone detected all cases with ALK rearrangement on initial screening. None of the ALK-rearranged tumors harbored coexisting EGFR mutations. CONCLUSIONS: Lung adenocarcinomas with ALK rearrangements are uncommon in the western population and represent a distinct entity of carcinomas with unique characteristics. For suspected cases, dual diagnostic testing, with FISH and immunohistochemistry, should be considered to accurately identify lung adenocarcinomas with ALK rearrangement.


Related Papers

No related papers found

Powered by citation graph analysis